What kind of drug does selinesol belong to?

Selinexor is an oral selective nuclear export inhibitor (SINE), which is a targeted anti-tumor drug. Its main function is to inhibit the function of XPO1 (export protein 1), thereby preventing tumor suppressor proteins in the nucleus from being transported to the cytoplasm. Through this mechanism, selinesol can restore the normal function of tumor suppressor proteins, induce apoptosis in cancer cells, and inhibit tumor growth. This unique mechanism of action makes selinesol a novel treatment option for relapsed or refractory cancers.

Currently, selinesol is widely used to treat multiple myeloma (MM) and refractory diffuse large B cell lymphoma (DLBCL). For patients with multiple myeloma, especially those who have not responded to multiple treatments, selinesol can significantly improve disease control rates. As an emerging targeted drug, it is approved as a treatment option in combination with other drugs to improve treatment effects and extend patient survival.

In clinical application, although the therapeutic effect of selinesol is significant, it is also accompanied by certain side effects, such as fatigue, loss of appetite, nausea, and hematological toxicity. Therefore, patients need to undergo strict medical monitoring when using it, and adjust the dosage or take appropriate treatment measures according to their physical condition. The oral form of selinesol provides patients with convenience of use, but puts higher requirements on drug compliance and side effect management.

In summary, selinesol is an innovative tumor treatment drug that provides new hope for patients with refractory cancer through its unique mechanism of action. Due to the high price, it has been included in the medical insurance system in some countries to reduce the burden on patients, but the specific scope of application and cost reimbursement policy need to be determined according to local conditions.

xa0

Reference materials:

https://www.drugbank.com/drugs/DB11866